BioLife Solutions (NASDAQ:BLFS) will release its earnings data after the market closes on Thursday, November 8th. Analysts expect BioLife Solutions to post earnings of $0.04 per share for the quarter.
BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.01. The company had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $5.20 million. BioLife Solutions had a return on equity of 2.24% and a net margin of 1.76%. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of BLFS traded down $0.46 during mid-day trading on Tuesday, reaching $11.90. 800 shares of the company’s stock traded hands, compared to its average volume of 145,764. The stock has a market cap of $202.31 million, a PE ratio of -57.62 and a beta of 1.46. BioLife Solutions has a 12 month low of $4.63 and a 12 month high of $26.35.
In related news, VP Todd Berard sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $17.23, for a total transaction of $51,690.00. Following the sale, the vice president now owns 37,583 shares of the company’s stock, valued at $647,555.09. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Raymond W. Cohen sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $19.70, for a total value of $197,000.00. Following the sale, the director now directly owns 43,031 shares in the company, valued at approximately $847,710.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 95,385 shares of company stock worth $1,836,984. 38.50% of the stock is owned by corporate insiders.
A number of research firms have recently weighed in on BLFS. ValuEngine cut BioLife Solutions from a “buy” rating to a “hold” rating in a report on Thursday, November 1st. B. Riley set a $22.00 price target on BioLife Solutions and gave the company a “buy” rating in a report on Wednesday, October 3rd. BidaskClub cut BioLife Solutions from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. TheStreet raised BioLife Solutions from a “d” rating to a “c-” rating in a report on Tuesday, September 11th. Finally, Maxim Group reaffirmed a “buy” rating and set a $26.00 price target on shares of BioLife Solutions in a report on Wednesday, September 5th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. BioLife Solutions currently has an average rating of “Buy” and a consensus target price of $22.00.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/11/06/biolife-solutions-blfs-set-to-announce-quarterly-earnings-on-thursday.html.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
See Also: What is a Market Correction?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.